[go: up one dir, main page]

BR9912594A - Inibição de doença de enxerto versus hospedeiro - Google Patents

Inibição de doença de enxerto versus hospedeiro

Info

Publication number
BR9912594A
BR9912594A BR9912594A BR9912594A BR9912594A BR 9912594 A BR9912594 A BR 9912594A BR 9912594 A BR9912594 A BR 9912594A BR 9912594 A BR9912594 A BR 9912594A BR 9912594 A BR9912594 A BR 9912594A
Authority
BR
Brazil
Prior art keywords
versus host
cells
oxidative stress
graft versus
disease
Prior art date
Application number
BR9912594A
Other languages
English (en)
Inventor
David Elliott Spaner
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of BR9912594A publication Critical patent/BR9912594A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"INIBIçãO DE DOENçA DE ENXERTO VERSUS HOSPEDEIRO". O desenvolvimento de doença enxerto versus hospedeiro em um paciente mamífero, sofrendo terapia de transplante de células para o tratamento de uma doença mediada por medula óssea, é prevenida ou aliviada submetendo-se pelo menos as células T da composição de transplante de células alogênicas, extra-corporeamente, a estresse oxidativo, em quantidades de dosagem apropriadas, tais como borbulhamento de uma mistura gasosa de ozónio e oxigênio, através de uma suspensão das células T. O processo também pode incluir a irradiação das células com luz UV, simultaneamente com a aplicação do estresse oxidativo. O estresse oxidativo induz a produção de citocina inflamatória reduzida e uma resposta proliferativa reduzida nas células T.
BR9912594A 1998-07-30 1999-07-30 Inibição de doença de enxerto versus hospedeiro BR9912594A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2244554 CA2244554A1 (en) 1998-07-30 1998-07-30 Inhibition of graft versus host disease
PCT/CA1999/000706 WO2000006703A2 (en) 1998-07-30 1999-07-30 Inhibition of graft versus host disease

Publications (1)

Publication Number Publication Date
BR9912594A true BR9912594A (pt) 2002-04-23

Family

ID=4162727

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912594A BR9912594A (pt) 1998-07-30 1999-07-30 Inibição de doença de enxerto versus hospedeiro

Country Status (16)

Country Link
US (2) US6258357B1 (pt)
EP (1) EP1100875A2 (pt)
JP (1) JP2002523332A (pt)
KR (1) KR20010072095A (pt)
CN (1) CN1314939A (pt)
AU (1) AU755630B2 (pt)
BR (1) BR9912594A (pt)
CA (1) CA2244554A1 (pt)
CZ (1) CZ2001316A3 (pt)
EA (1) EA200100195A1 (pt)
IL (1) IL141007A0 (pt)
MX (1) MXPA01001144A (pt)
NO (1) NO20010490L (pt)
NZ (1) NZ509387A (pt)
WO (1) WO2000006703A2 (pt)
ZA (1) ZA200101614B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE516133C2 (sv) * 1999-02-25 2001-11-19 Lundblad Leif J I Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
CA2324199A1 (en) * 2000-10-25 2002-04-25 Vasogen Ireland Limited Chronic lymphocytic leukemia treatment
BRPI0211570B8 (pt) * 2001-07-31 2021-05-25 Anormed Inc uso de 1'-[1,4-fenileno-bis-(metileno)-bis-1,4,8,11- tetrazaciclotetradecano ou um sal farmaceuticamente aceitável do mesmo na preparação de uma composição para coletar células progenitoras e/ou tronco
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
ES2422193T3 (es) * 2002-06-28 2013-09-09 Life Technologies Corp Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas
WO2004094463A2 (en) * 2003-04-18 2004-11-04 University Of Florida Research Foundation, Inc. Peptide inhibitors of autophosphorylation protein kinases
US20090232834A1 (en) * 2005-07-18 2009-09-17 Al-Harbi Saleh A Methods and Agents to Treat Autoimmune Diseases
WO2008128069A1 (en) * 2007-04-11 2008-10-23 Roger Deutsch Methods for diagnosing biological samples containing stem cells
CA2743697A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
EP3219793A1 (en) * 2012-01-05 2017-09-20 Taipei Veterans General Hospital Preparation of cell transplant
RU2508924C1 (ru) * 2013-02-21 2014-03-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Способ профилактики и лечения отторжения почечного трансплантата
JP7445946B2 (ja) * 2019-06-12 2024-03-08 国立大学法人九州大学 性質変化方法及びプラズマ生成装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
JPH11511746A (ja) * 1995-05-25 1999-10-12 バクスター、インターナショナル、インコーポレイテッド 同種幹細胞移植後の癌の同種細胞治療
DE69609943T2 (de) * 1996-03-29 2001-04-12 The Procter & Gamble Company, Cincinnati Bewertungsmethode für wegwerfbare absorbierende Strukturen

Also Published As

Publication number Publication date
US20010028879A1 (en) 2001-10-11
NO20010490L (no) 2001-03-29
AU755630B2 (en) 2002-12-19
ZA200101614B (en) 2002-01-02
KR20010072095A (ko) 2001-07-31
WO2000006703A2 (en) 2000-02-10
IL141007A0 (en) 2002-02-10
AU5143399A (en) 2000-02-21
WO2000006703A3 (en) 2000-05-04
CZ2001316A3 (cs) 2001-10-17
NO20010490D0 (no) 2001-01-29
US6258357B1 (en) 2001-07-10
EP1100875A2 (en) 2001-05-23
NZ509387A (en) 2002-10-25
CN1314939A (zh) 2001-09-26
MXPA01001144A (es) 2002-04-24
CA2244554A1 (en) 2000-01-30
JP2002523332A (ja) 2002-07-30
EA200100195A1 (ru) 2001-10-22

Similar Documents

Publication Publication Date Title
BR9912594A (pt) Inibição de doença de enxerto versus hospedeiro
DE60129943D1 (de) Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen
ES2080837T3 (es) Tratamiento de estados y enfermedades.
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
ATE65505T1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
BR9712765A (pt) Processos e composições para estimulação do crescimento de neurites utilizando compostos com afinidade para fkbp12 em combinação com fatores neurotróficos
BR9607601A (pt) Uso de ácido hialurÈnico para o tratamento de cistite intersticial
Khalil et al. Single-dose mRNA therapy via biomaterial-mediated sequestration of overexpressed proteins
DE69434445D1 (de) Verfahren zur sterilisation biologischer zusammensetzungen und das dabei erhaltene produkt
Saito et al. Acceleration of bone formation during fracture healing by injectable collagen powder and human basic fibroblast growth factor containing a collagen‐binding domain from Clostridium histolyticum collagenase
NO924323L (no) Nye hybridtransformerende vekstfaktorer
DE69934987D1 (de) Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
DE69911629D1 (de) Zusammensetzungen und deren verwendung zur hemmung von angiogenese
Bonfim et al. Effectiveness of 780 nm photobiomodulation as adjunct treatment for bone exposed fractures: A pilot study on radiograph, pain, and cytokines analysis
TR199901385T2 (xx) Piperidin t�revleri.
PT883406E (pt) Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente
AR003974A1 (es) Una nueva proteina mp52 arg humana, un proceso para la produccion y aislacion de la misma y composiciones farmaceuticas que la contienen
DE60103658D1 (de) Ex-vivo unter oxidativen stress behandelte cll-zellen zur behandlung chronischer lymphozytärer läukemie (cll)
Rademakers et al. The Effect of Local Purified Exosome Product, Stem Cells, and Tacrolimus on Neurite Extension
NZ503770A (en) Treatment of stress and associated symptoms by stressing blood cells and re-introducing them into the body
BR9713130A (pt) Região promotora de bmp-4 e seus fragmentos, vetor compreendendo uma região promotora de bmp-4 ou seus fragmentos, célula hospedeira, processo para a identificação de agentes terapêuticos para a prevenção e/ou tratamento da osteoporose, e, uso de ici 164384.
ES2117717T3 (es) Tratamiento de tumores con factores neurotroficos e inhibidores de la proliferacion celular.

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO DE TRANSFERENCIA NO 028901/RJ DE 05/06/2002, POR FALTA DE FUNDAMENTACAO LEGAL.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.

B15K Others concerning applications: alteration of classification

Ipc: C12N 5/0783 (2010.01), A61K 35/17 (2015.0